EORTC SPECTARare launched in 2016, the first prospective registry and tissue biomarker study for rare cancers.

RareCan1; A basket prospective stratified clinical trial of three agents in rare cancers- A European first

We are collaborating with EORTC and pharmaceutical companies with strong rare cancer pipelines, in order to develop a novel inclusive clinical trial that will evaluate efficacy, toxicity, cost effectiveness, quality and safety.

OneĀ idea is to develop a component with Healthcare at Home in order to deliver the agents to the patients wherever they may be located.